These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11480481)

  • 1. Monoclonal antibody therapy for Crohn's disease.
    Selby W
    Intern Med J; 2001 Mar; 31(2):73-4. PubMed ID: 11480481
    [No Abstract]   [Full Text] [Related]  

  • 2. Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?
    Cuffari C; Lichtenstein GR
    Gastroenterology; 2003 Jun; 124(7):1988-90. PubMed ID: 12806638
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
    Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Maintenance treatment by anti-tumor necrosis factor monoclonal antibody in Crohn's disease--long-term effects and safety].
    Matsui T
    Nihon Shokakibyo Gakkai Zasshi; 2008 May; 105(5):649-58. PubMed ID: 18460853
    [No Abstract]   [Full Text] [Related]  

  • 5. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease.
    Ritz MA; Jost R
    Inflamm Bowel Dis; 2001 Nov; 7(4):327. PubMed ID: 11720324
    [No Abstract]   [Full Text] [Related]  

  • 7. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
    Vermeire S; Noman M; Van Assche G; Baert F; Van Steen K; Esters N; Joossens S; Bossuyt X; Rutgeerts P
    Gastroenterology; 2003 Jul; 125(1):32-9. PubMed ID: 12851868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist.
    Angelucci E; Cocco A; Viscido A; Vernia P; Caprilli R
    Inflamm Bowel Dis; 2007 Aug; 13(8):1059-61. PubMed ID: 17387676
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
    Shanahan F
    Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074
    [No Abstract]   [Full Text] [Related]  

  • 10. Pericarditis as a complication of infliximab therapy in Crohn's disease.
    Burke JP; Kelleher B; Ramadan S; Quinlan M; Sugrue D; O'Donovan MA
    Inflamm Bowel Dis; 2008 Mar; 14(3):428-9. PubMed ID: 17924565
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction of pustular lesions during infliximab therapy for Crohn's disease.
    Pérez-Pérez L; Caeiro JL; Fabeiro JM; Allegue F; Zulaica A
    Acta Derm Venereol; 2008; 88(3):292-3. PubMed ID: 18480940
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy.
    Dubcenco E; Ottaway CA; Chen DL; Baker JP
    Eur J Gastroenterol Hepatol; 2006 May; 18(5):565-6. PubMed ID: 16607158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab infusion reactions: desensitizing ourselves to the danger.
    Persley KM
    Inflamm Bowel Dis; 2004 Jan; 10(1):62-3. PubMed ID: 15058530
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe agranulocytosis following first infliximab infusion in Crohn's disease.
    Rosales-Zábal JM; Fernández-Pérez F; Albandea-Moreno C; Vera-Rivero FM; Navarro-Jarabo JM
    Inflamm Bowel Dis; 2011 Nov; 17(11):E147-8. PubMed ID: 21830280
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic amyloidosis with Crohn's disease treated with infliximab.
    Park YK; Han DS; Eun CS
    Inflamm Bowel Dis; 2008 Mar; 14(3):431-2. PubMed ID: 17932971
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.
    Rampton DS
    Gut; 2005 Oct; 54(10):1360-2. PubMed ID: 16113045
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease.
    Izbéki F; Nagy F; Szepes Z; Kiss I; Lonovics J; Molnár T
    Inflamm Bowel Dis; 2008 Mar; 14(3):429-31. PubMed ID: 17973302
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab-induced thrombocytopenia in an elderly patient with ileocolonic Crohn's disease.
    Mocciaro F; Russo G; Di Mitri R; Marino A
    Inflamm Bowel Dis; 2013; 19(4):E52-3. PubMed ID: 22535599
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS
    J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S36-9. PubMed ID: 11685974
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
    Lichtenstein GR
    Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.